Differences between domestic and imported Jisandai (Epclusa) drugs, as well as price and efficacy comparisons

Epclusa (Epclusa) is a direct antiviral drug (DAA), used to treat chronic hepatitis C virus (HCV) infection and is suitable for patients with multiple genotypes. It blocks viral replication and assembly by inhibiting NS5A and NS5B proteins, thus achieving the effect of clearing HCV. The domestically marketed Jisandai drugs are mainly original drugs and domestic generic drugs, with different prices and efficacy, but generally they can achieve high virological response rates.

In terms of the difference between domestically produced and imported drugs, most of the domestically produced Jisandai drugs are domestically produced generic drugs. Their main advantages are that they are relatively low-priced and can be reimbursed through medical insurance in the domestic medical system, making it convenient for patients to take drugs for a long time. Imported original drugs have more complete quality and clinical trial data and are usually more expensive, but they are not much different from domestic generic drugs in terms of efficacy and safety. Domestic patients can choose a suitable version based on their own financial situation and medical insurance policy.

In terms of price, the domestic market price of Jisandai is about more than 3,000 yuan, and it has been included in the scope of medical insurance reimbursement. Patients who meet the conditions can enjoy a certain proportion of reimbursement to reduce their financial burden. In comparison, the price of generic drugs in India and Bangladesh is lower, only a few hundred yuan per box, and the drug ingredients are basically the same as the original drugs, and the efficacy is similar. Therefore, some patients will choose these overseas generic drugs when their financial conditions are limited or when they go abroad for medical treatment.

In terms of efficacy, whether it is a domestic generic drug or an imported original drug, Jisandai can achieve a high virological response rate (SVR) in clinical practice, usually above 95%. Clinical practice shows that there is no significant difference in virus clearance rate and recurrence rate after patients strictly follow the doctor's instructions and complete the full course of treatment. However, imported drugs may provide more clinical data and support in terms of medication compliance, drug source protection and adverse reaction monitoring. Therefore, when choosing Jisandai, patients should consider their economic situation, medical insurance policy and doctor’s advice to reasonably choose the version that suits them.

Reference materials:https://www.drugs.com/